

IN THE SPECIFICATION:

Please add the following paragraph at page 1, after line 5 and before line 6.

“This application a U.S. national stage application of PCT/US2004/013379 filed April 30, 2005, which is a continuation-in-part of application Ser. No. 10/454,663, filed June 4, 2003. The entire contents of these applications are herein incorporated by reference.”

Please amend the paragraph at page 1, lines 6-19

“The entire contents of the following applications and patents are herein incorporated by reference: This application is a continuation-in-part of application Serial No. 09/982,262, filed October 18, 2001, which is a continuation-in-part of application Serial No 09/659,288, filed September 12, 2000 (abandoned), which is a continuation of application Serial No. 09/128,496, filed August 3, 1998 (U.S. Patent No. 6,169,079), which is a continuation of application Serial No. 08/440,740, filed May 12, 1995 (U.S. Patent No. 5,843,738), which is a continuation-in-part of application Serial No. 08/063,167 filed May 17, 1993 (U.S. Patent No. 5,514,788), which is a continuation of application Serial No. 07/969,151 filed February 10, 1993 (abandoned), which is a continuation-in-part of application Serial No. 08/007,997 filed January 21, 1993 (U.S. Patent No. 5,591,623). The entire contents of these applications and patents is incorporated herein by reference.”

Please amend the paragraph at page 8, lines 32-35 as follows.

“FIGURE 18 is a graph showing the effects of ICAM-1 antisense oligonucleotides (ISIS 13315 and 17481) on the number of eosinophilscosinophils in bronchiolar lavage (BAL) fluid in an ovalbumin- induced mouse asthma model after intratracheal oligonucleotide administration.”

Please amend the paragraph at page 26, lines 2-19 as follows.

“A further class of oligonucleotide mimetic is referred to as cyclohexenyl nucleic acids (CeNA). The furanose ring normally present in ~~ana~~ DNA/RNA molecule is replaced with a ~~eyelohenyl~~ cyclohexenyl ring. CeNA DMT protected phosphoramidite monomers have been prepared and used for oligomeric compound synthesis following classical phosphoramidite chemistry. Fully modified CeNA oligomeric compounds and oligonucleotides having specific positions modified with CeNA have been prepared and studied (see Wang et al., J. Am. Chem. Soc., 2000,122, 8595-8602). In general the incorporation of CeNA monomers into a DNA chain increases its stability of a DNA/RNA hybrid. CeNA oligoadenylates formed complexes with RNA and DNA complements with similar stability to the native complexes. The study of incorporating CeNA structures into natural nucleic acid structures was shown by NMR and circular dichroism to proceed with easy conformational adaptation. Furthermore the incorporation of CeNA into a sequence targeting RNA was stable to serum and able to activate E. coli RNase resulting in cleavage of the target RNA strand.”

Please amend the paragraph at page 30, lines 11-19 as follows.

“Another class of oligonucleotide mimetic, ~~is~~ referred to as phosphonomonoester nucleic acids, incorporate a phosphorus group in ~~a backbone~~ the backbone. This class of ~~olignucleotide~~oligonucleotide mimetic is reported to have useful physical and biological and pharmacological properties in the areas of inhibiting gene expression (antisense oligonucleotides, ribozymes, sense oligonucleotides and triplex-forming oligonucleotides), as probes for the detection of nucleic acids and as auxiliaries for use in molecular biology.”